Neoadjuvant chemotherapy for gastric cancer in Japan: A standing position by comparing with adjuvant chemotherapy

Surgery Today

Volumn 44, Issue 1, 2014, Pages 11-21

  Yoshikawa, Takaki ^a,b   Rino, Yasushi ^b   Yukawa, Norio ^b   Oshima, Takashi ^b   Tsuburaya, Akira ^a   Masuda, Munetaka ^b  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Clinical trial; Evidence; Gastric cancer; Neoadjuvant chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; EUROPE; JAPAN; MEDICAL SOCIETY; MICROMETASTASIS; PATIENT COMPLIANCE; POSTOPERATIVE CARE; RECTUM CARCINOMA; REVIEW; STOMACH CANCER; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR REGRESSION;

ADENOCARCINOMA, SCIRRHOUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; GASTRECTOMY; HUMANS; JAPAN; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84891744783     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0529-1     Document Type: Review

References (50)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18-29.
2. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol. 2003;21:274s-5s.
3. Cardoso R, Coburn N, Seevaratnam R, Mahar A, Helyer L, Law C, et al. A systematic review of patient surveillance after curative gastrectomy for gastric cancer: a brief review. Gastric Cancer. 2012;. doi: 10.1007/s10120-012-0142-9.
4. Okuyama T, Korenaga D, Edagawa A, Itoh S, Oki E, Kawanaka H, et al. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery. Surg Today. 2012;42:734-40.
5. Kubo N, Oki E, Ohgaki K, Shibahara K, Imamura I, Sadanaga N, et al. Surgical resection following combination chemotherapy with oral S-1 and biweekly docetaxel in a patient with advanced gastric cancer and a prior coronary artery bypass graft with the right gastroepiploic artery: report of a case. Surg Today. 2011;41:1531-7.
6. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441-7.
7. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35:1059-64.
8. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000;11:837-43.
9. Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori. 2002;88:21-7.
10. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999;354:273-7.
11. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21:2282-7.
12. Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer. 2011;14:212-8.
13. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30.
14. Tanizawa Y, Terashima M. Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric Cancer. 2010;13:137-48.
15. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60:1449-72.
16. NCCN. NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer Version 2.2011 [online]. http://www.nccn.org/professionals/physician-gls/pdf/ gastric.pdf (2011).
17. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908-14.
18. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439-49.
19. Lee J. Lim do H, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268-73.
20. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20.
21. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387-93.
22. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-21.
23. Yoshikawa T, Sasako M. Gastrointestinal cancer: adjuvant chemotherapy after D2 gastrectomy for gastric cancer. Nat Rev Clin Oncol. 2012;9:192-4.
24. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188-96.
25. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
26. Kim YH, Koizumi W, Lee KH, Kishimoto T, Chung HC, Hara T, et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial. Proceedings of the 2011 Gastrointestinal Cancers Symposium: 7 (abstr 7), 2011.
27. Fujii M, Kim YH, Satoh H, Hosaka H, Kim T, Tsuji A, et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial update. J Clin Oncol 29 (suppl; abstr 4016), 2011.26.
28. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7.
29. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261-7.
30. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996-2004.
31. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-9.
32. Kodera Y, Ishiyama A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, et al. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer. 2010;13:197-203.
33. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67:1423-8.
34. Kobayashi M, Tsuburaya A, Nagata N, Miyashita Y, Oba K, Sakamoto J. A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer. 2006;9:114-9.
35. Tsuburaya A, Sakamoto J, Morita S, Kodera Y, Kobayashi M, Miyashita Y, et al. A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial. Jpn J Clin Oncol. 2005;35:672-5.
36. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305:2335-42.
37. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
38. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-21.
39. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-8.
40. Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. 2011;14:97-100.
41. Tokunaga M, Ohyama S, Hiki N, Fukunaga T, Aikou S, Yamaguchi T. Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol. 2010;17:2031-6.
42. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y. Should schirrhous gastric carcinoma be treated surgically? Clinical experiences with 233 cases and a retrospective analysis of prognosticators. Hepatogastroenterology. 2011;48:1509-12.
43. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015-22.
44. Yoshikawa T, Nakamura K, Tsuburaya A, Sano T, Mizusawa J, Katai H, et al. A phase II study of preoperative chemotherapy with S-1 (S) and cisplatin (P) followed by D3 gastrectomy for gastric cancer (GC) with extensive lymph node metastasis (ELM): Survival results of JCOG0405. In: Proceedings of the 2011 Gastrointestinal Cancers Symposium: 65 (abstr 70), 2011.
45. Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer. 2009;12:37-42.
46. Iwasaki Y, Sasako M, Sano T, Yamamoto S, Sato A, Tsujinaka T, et al. Phase II study of preoperative S-1 and cisplatin in patients with clinically resectable type 4 and large type 3 gastric cancer. Japan Clinical Oncology Group Study (JCOG0210). In: Proceedings of the 2006 Gastrointestinal Cancers Symposium: 120 (abstr 72), 2006.
47. Yoshikawa T, Omura K, Kobayashi O, Nashimoto A, Takabayashi A, Yamada T, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546-51.
48. Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, et al. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Jpn J Clin Oncol. 2010;40:369-72.
49. Watanabe T, Yoshikawa T, Kameda Y, Aoyama T, Hayashi T, Ogata T, et al. Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case. Surg Today. 2012;42:983-7.
50. Yoshikawa T, Taguri M, Sakuramoto S, Kunisaki C, Fukunaga T, Ito S, et al. A comparison of multimodality treatment: two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer: a randomized phase II trial (COMPASS-D trial). Jpn J Clin Oncol. 2012;42:74-7.